The Caen Normandy University Hospital is improving cardiac and renal care for patients

The Caen Normandy University Hospital is a winner for two prestigious Hospital Clinical Research Projects this year.

These PHRC grants support promising research projects led by healthcare professionals from the cardiology and nephrology departments of the University Hospital, aiming to improve the medical management of two major issues: the optimal duration of medical treatment after cardiac intervention to reduce the risk of bleeding in elderly patients, and prevention through the administration of a new anticoagulant that could offer better protection against blood clots in patients with renal failure.

These medical advances aim to improve patient care and offer better treatment prospects.

"SOLOPCI Trial" Project

Led by Dr. Vincent Roule, Professor Farzin Beygui , and Professor Paul-Ursmar Milliez of the cardiology department at Caen Normandy University Hospital, this project aims to determine the ideal duration of medical treatment following coronary artery bypass surgery. The objective is to reduce the risk of bleeding while maintaining effective protection against thrombotic events, particularly myocardial infarction and/or stroke, in an elderly patient population. The researchers hypothesize that a very short course of antiplatelet therapy could further reduce bleeding without compromising protection against thrombotic events, potentially revolutionizing medical practice by becoming the default strategy for this growing and understudied patient population.

APIDP2 Trial Project

Led by Dr. Maxence Ficheux and Professor Thierry Lobbedez of the Nephrology Department at Caen Normandy University Hospital, this project focuses on the treatment of atrial fibrillation in patients undergoing peritoneal dialysis. Patients with kidney failure on peritoneal dialysis are often excluded from clinical trials, making the identification of an effective treatment even more challenging. The study aims to evaluate a new anticoagulant that could offer better protection against blood clots while reducing the risk of bleeding in this specific population.

If this study confirms the hypothesis formulated, this new anticoagulant could offer a significant advantage in terms of reducing bleeding compared to standard treatment, which would be a major advance in the treatment of this specific population.

The commitment of the Caen Normandy University Hospital to translational scientific research

These two PHRC ( Hospital Clinical Research Program) grants demonstrate the commitment of Caen Normandy University Hospital to scientific research , aiming to implement cutting-edge scientific knowledge to improve patient care and quality of life. The results of these studies could have a significant impact on clinical practices and pave the way for new therapeutic approaches.

The Caen Normandy University Hospital will continue to invest in research and innovation to offer leading medical advances to its patients, with an emphasis on crucial health issues such as those addressed in the SOLOPICI and APIDP2 projects.